title: [State of the art in nuclear imaging for the diagnosis of bone metastases].
abstract: Cancers prone to spread to bone include prostate, lung, kidney, breast and thyroid cancers. While bone scanner has been widely used in the past decades, PET-based imaging modalities are increasingly used. Current modalities of PET imaging of bone metastases include tumor and inflammatory targeting with FDG-PET, bone imaging with NaF-PET, and direct cancer-specific markers such as FDOPA-PET or PET using choline. The cancer-specific metastatic patterns and the relative prognosis conferred by osseous metastases (versus visceral metastases) may determine the need for bone scan, FDG-PET for the detection of bone metastases. Because some cancers have a mixed skeletal and visceral, cocktails PET radiopharmaceuticals may also be discussed in the future. The cancer-specific context and performances of bone scan and PET imaging are discussed.
authors.affiliation: Centre Antoine-Lacassagne, médecine nucléaire, 33, avenue de Valombrose, 06136 Nice cedex, France.
authors.forename: Matthieu-John
authors.initials: MJ
authors.lastname: Ouvrier
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
authors.forename: Juliette
authors.initials: J
authors.lastname: Thariat
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D012969:Sodium Fluoride
keywords: FDG; NaF; PET; bone metastasis; bone scan